Protherics signs ReGel⢠licensing agreement with Myungmoon Pharm
Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that it has signed a licensing agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company, granting it the rights to develop anti-inflammatory products using Protherics' local, sustained release drug delivery system ReGel™. Teva Receives Positive Feedback on Second AOK Tender in Germany
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced that it has received notification from Allgemeinen Ortskrankenkassen (AOK), Germany's largest health insurance company, on the results of the most recent tender for finished dosage pharmaceutical products. Teva is very pleased to have been awarded a significant increase in the number of molecules for which it can contract to supply during 2008-2009; compared to the six products it was awarded in the first tender earlier this year. InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board
InferMed has a long-standing relationship with Cancer Research UK, and was backed by the charity at its formation in 1999. A research relationship continues with Cancer Research UK, which remains InferMed's largest institutional shareholder.
Business & Industry
- Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
- Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
- Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
- Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
- Bayer transforms pharma business through breakthrough innovation in healthcare
Research & Development
- Obesity, impaired metabolic health and COVID-19
- COVID-19 has multiple faces
- Metformin use reduces risk of death for patients with COVID-19 and diabetes
- New England Journal of Medicine publishes COVID-19 treatment trial results
- Scientists identify 'immune cop' that detects SARS-CoV-2
- New findings help explain how COVID-19 overpowers the immune system
- New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
- FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
- EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2